Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review

Viktor Mravčík, Lisa Strada, Josef Stolfa, Vladimir Bencko, Teodora Groshkova, Jens Reimer, Bernd Schulte, Viktor Mravčík, Lisa Strada, Josef Stolfa, Vladimir Bencko, Teodora Groshkova, Jens Reimer, Bernd Schulte

Abstract

Introduction and methods: Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment.

Results: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient's part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider's part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role. Strategies to improve the HCV treatment rate among PWID involve pretreatment management and assessment, a multidisciplinary approach, management of side effects, and enhanced education and counseling.

Conclusion: Specific factors are associated with poorer treatment outcomes in PWID on the side of both the patient and the treatment system. However, given that PWID can achieve treatment adherence and sustained virologic response rates comparable with those in nondrug users, drug use per se should not be considered a criterion for exclusion from treatment. Further development of measures leading to higher uptake of treatment and adherence in PWID and appropriate adaptation of HCV treatment guidelines represent important tools in this regard.

Keywords: adherence; efficacy; hepatitis C virus; people who inject drugs; treatment uptake.

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342.
    1. Seeff LB. The history of the “natural history” of hepatitis C (1968–2009) Liver Int. 2009;29(Suppl 1):89–99.
    1. World Health Organization Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44(1):20–29.
    1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–2441.
    1. Alter MJ. HCV routes of transmission: what goes around comes around. Semin Liver Dis. 2011;31(4):340–346.
    1. Urbánek P. Virová hepatitida C. [Hepatitis C virus] Adiktologie. 2010;10(2):102–109. Czech.
    1. Pondé RA. Hidden hazards of HCV transmission. Med Microbiol Immunol. 2011;200(1):7–11. Czech.
    1. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–358.
    1. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–583.
    1. European Monitoring Centre for Drugs and Drug Addiction Annual Report 2012 The State of the Drugs Problem in Europe Luxembourg: Publications Office of the European Union; 2012Available from: Accessed September 1, 2013
    1. Perz JF, Armstrong GL, Farrington LA, Hutin Y, Bell B. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
    1. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126–133.
    1. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009;16(5):352–358.
    1. Strathdee S, Latka M, Campbell J, et al. Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005;40(Suppl 5):S304–S312.
    1. Iversen J, Topp LJ, Maher L.Australian NSP Survey National Data Report 1995–2010 Sydney, Australia: Faculty of Medicine, The Kirby Institute for Infection and Immunity in Society, University of New South Wales; 2011Available from: Accessed September 1, 2013
    1. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34–41.
    1. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008;103(5):1283–1297.
    1. van den Berg CH, Grady BP, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One. 2011;6(11):e27555.
    1. Grebely J, Prins M, Hellard M, et al. International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12(5):408–414.
    1. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int. 2011;31(Suppl 1):62–67.
    1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–521.
    1. John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010;53(2):245–251.
    1. Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis. 2007;39(Suppl 1):S4–S7.
    1. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31(4):331–339.
    1. Nizar NZ. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13(2):223–235.
    1. Cooreman MP, Schoondermark-Van de Ven EM. Hepatitis C virus: biological and clinical consequences of genetic heterogeneity. Scand J Gastroenterol Suppl. 1996;218:106–115.
    1. Nousbaum JB. Genomic subtypes of hepatitis C virus: epidemiology, diagnosis and clinical consequences. Bull Soc Pathol Exot. 1998;91(1):29–33. French.
    1. European Association of the Study of the Liver 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32(Suppl 1):2–8.
    1. Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat. 2007;14(Suppl 1):82–88.
    1. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429–2438.
    1. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44(1):97–103.
    1. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43(5):954–960.
    1. Sanchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131(2):451–460.
    1. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 with rapid virological response. Gastroenterology. 2008;135(2):451–458.
    1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepattis C virus infection. N Engl J Med. 2002;347(13):975–982.
    1. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009;29(7):1051–1055.
    1. Craine N, Hickman M, Parry JV, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect. 2009;137(9):1255–1265.
    1. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8:CD004145.
    1. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74–83.
    1. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978–1988.
    1. Vickerman P, Martin NK, Hickman M. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings – implications for intervention impact. Drug Alcohol Depend. 2012;123(1–3):122–131.
    1. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107(11):1984–1995.
    1. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137–1144.
    1. Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. June2013 [Epub ahead of print.]
    1. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol. 2011;274(1):58–66.
    1. Vickerman P, Martin N, Hickman M. Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend. 2010;113(2–3):83–85.
    1. Zeiler I, Langlands T, Murray JM, Ritter A. Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend. 2010;110(3):228–233.
    1. Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49–57.
    1. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend. 2007;88(1):49–53.
    1. Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol. 2011;23(1):23–31.
    1. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270–277.
    1. Harris KA, Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med. 2010;4(1):20–26.
    1. Grebely J, Petoumenos K, Matthews GV, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: the ATAHC Study. Drug Alcohol Depend. 2010;107(2–3):244–249.
    1. Gazdag G, Horváth G, Szabó O, Ungvari GS. Referral of intravenous drug users for antiviral treatment: effectiveness of hepatitis C case-finding programmes. Cent Eur J Public Health. 2012;20(3):223–225.
    1. Slezáková S, Okruhlica L. Motivácia na liečbu hepatitídy C u užívatel′ov psychoaktívnych látok. [Motivation for treatment of HCV infection among drug users] Adiktologie. 2011;11(3):142–146. Slovak.
    1. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18(5):437–443.
    1. Hopwood M, Treloar C. The drugs that dare not speak their name: injecting and other illicit drug use during treatment for hepatitis C infection. Int J Drug Policy. 2007;18(5):374–380.
    1. Mimiaga MJ, Safren SA, Dvoryak S, Reisner SL, Needle R, Woody G. “We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2010;22(11):1305–1313.
    1. Sarang A, Rhodes T, Sheon N, Page K. Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse. 2010;45(6):813–864.
    1. Cooper CL, Giordano C, Mackie D, Mills EJ. Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision. Ther Clin Risk Manag. 2010;6:207–212.
    1. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207(Suppl 1):S19–S25.
    1. Tungol A, Rademacher K, Schafer JA. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm. 2011;17(9):685–694.
    1. Assis DN, Lim JK. New pharmacotherapy for hepatitis C. Clin Pharmacol Ther. 2012;92(3):294–305.
    1. Rockstroh J. New agents for hepatitis C and the challenges in treating co-infected patients. J Int AIDS Soc. 2012;15(6):18115.
    1. Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol. 2006;18(10):1057–1063.
    1. Myles A, Mugford GJ, Zhao J, Krahn M, Wang PP. Physicians′ attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol. 2011;25(3):135–139.
    1. Litwin AH, Kunins HV, Berg KM, et al. Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat. 2007;33(1):99–105.
    1. Mravčík V. Léčba VHC u injekčních uživatelů drog vČR – průzkum mezi centry pro léčbu virových hepatitid. [HCV Treatment of Injecting Drug Users in the Czech Republic – Survey among Viral Hepatitis Treatment Centres] Adiktologie. 2012;12(1):10–22. Czech.
    1. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res. 2002;8(1):45–49.
    1. Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2011;55(4):1058–1069.
    1. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36(5 Suppl 1):S210–S219.
    1. Hartz A, He T. Why is greater medication adherence associated with better outcomes. Emerg Themes Epidemiol. 2013;10(1):1.
    1. Weiss JJ, Brau N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C – building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther. 2009;30(1):14–27.
    1. Grebely J, Matthews GV, Hellard M, et al. ATAHC Study Group Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011;55(1):76–85.
    1. Robaeys G, Van Vlierberghe H, Mathei C, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006;18(2):159–166.
    1. Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22(9):1050–1057.
    1. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46(4):991–998.
    1. Gazdik F, Gazdikova K, Laktis K, et al. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin. Bratisl Lek Listy. 2009;110(2):77–84.
    1. Schulte B, Schütt S, Brack J, et al. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend. 2010;109(1–3):248–251.
    1. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561–573.
    1. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis. 2012;55(6):806–816.
    1. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010;138(1):123–135.
    1. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19(9):741–747.
    1. Reimer J, Schulte B, Castells X, et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin Infect Dis. 2005;40(Suppl 5):373–378.
    1. Calvaruso V, Craxi A. European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32(Suppl 1):2–8.
    1. Robaeys G, Grebely J, Mauss S, et al. International Network on Hepatitis in Substance Users Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57(Suppl 2):S129–S137.
    1. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34(1):188–193.
    1. Reimer J, Haasen C. Need-adapted HCV-treatment setting for injection drug users. Lancet. 2009;373(9681):2090–2091.
    1. Nguyen OK, Dore GJ, Kaldor JM, Hellard ME. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study. Int J Drug Policy. 2007;18(5):447–451.
    1. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat. 2010;17(12):839–844.
    1. Teasdale KE, Keren KM, Kiel A, Becker K. Improving services for prevention and treatment of substance misuse for Aboriginal communities in a Sydney Area Health Service. Drug Alcohol Rev. 2008;27(2):152–159.
    1. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis. 2005;40(Suppl 5):S339–S345.
    1. Moussalli J, Delaquaize H, Boubilley D, et al. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract. 2010;2010:pii261472.
    1. Hagan H, Strauss SM, Astone JM, Des Jarlais DC. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clin Infect Dis. 2005;40(Suppl 5):S297–S303.
    1. Strauss SM, Astone J, Vassilev ZP, Des Jarlais DC, Hagan H. Gaps in the drug-free and methadone treatment program response to hepatitis C. J Subst Abuse Treat. 2003;24(4):291–297.
    1. Strauss SM, Falkin GP, Vassilev Z, Des Jarlais DC, Astone J. A nationwide survey of hepatitis C services provided by drug treatment programs. J Subst Abuse Treat. 2002;22(2):55–62.
    1. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345(3):211–215.
    1. Smith BJ, Bauman AE, Chen J, et al. Hepatitis C in Australia: impact of a mass media campaign. Am J Prev Med. 2006;31(6):492–498.
    1. Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271(2):115–120.
    1. Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992–1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(5):505–511.
    1. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605–611.
    1. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125(1):80–88.
    1. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43(2):250–256.
    1. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence. 2008;93:1–2. 141–147.
    1. Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev. 2008;(2):177–187.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere